Elan dumps MS candidate and revels in EDT decision
This article was originally published in Scrip
Executive Summary
Irish drug-maker Elan has made a "business portfolio decision" to discontinue development of ELND002 in multiple sclerosis (MS). Elan made the announcement during its fourth quarter and full year 2011 results, where it revealed that excluding the recently divested Elan Drug Technology (EDT) business, revenues were up by 19% over full-year 2010 to $1.07 billion.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.